
-
Alaunos Therapeutics NasdaqCM:TCRT Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
Location: 2617 Bissonnet Street, Houston, TX, 77005, United States | Website: https://www.alaunos.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
3.425M
Cash
1.091M
Avg Qtr Burn
-1.243M
Short % of Float
3.06%
Insider Ownership
5.98%
Institutional Own.
4.33%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued | |
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued | |
TCR-T targeting neoantigens Details Cancer, Solid tumor/s | Failed Discontinued | |
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued |